MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, WGS had $21,848K increase in cash & cash equivalents over the period. $9,595K in free cash flow.

Cash Flow Overview

Change in Cash
$21,848K
Free Cash flow
$9,595K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-7,635 4,280
Depreciation and amortization expense
6,474 11,869
Stock-based compensation expense
10,586 11,796
Change in fair value of financial liabilities
3,401 -1,081
Deferred tax expense (benefit)
246 202
Provision for excess and obsolete inventory
29 123
Legal reserves
-810 0
Change in third party payor reserves
-3,732 -5,014
Other
995 1,387
Accounts receivable
12,910 9,889
Inventory
-1,332 1,404
Accounts payable and accrued expenses
-2,014 7,199
Other assets and liabilities
-10,721 8,894
Net cash provided by (used in) operating activities
15,767 20,602
Acquisition of business, net of cash acquired
0 33,195
Purchases of property and equipment
6,172 8,498
Purchases of marketable securities
5,765 30,770
Proceeds from sales of marketable securities
0 0
Proceeds from maturities of marketable securities
7,250 26,705
Net cash used in investing activities
-4,687 -45,758
Proceeds from offerings, net of issuance costs
11,802 13,766
Proceeds from issuance of common stock pursuant to employee stock purchase plan
0 1,262
Exercise of stock options
182 800
Long-term debt principal payments
304 602
Finance lease principal payments
912 1,162
Net cash provided by financing activities
10,768 14,064
Net increase (decrease) in cash, cash equivalents and restricted cash
21,848 -11,092
Cash and cash equivalents at beginning of period
86,202 -
Cash and cash equivalents at end of period
96,958 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

GeneDx Holdings Corp. (WGS)

GeneDx Holdings Corp. (WGS)